Wearable blood pressure monitors: which startup is ahead?
In our wearable technology market deck, you will find everything you need to understand the market
SUMMARY
Sky Labs is currently ahead in wearable blood pressure monitoring because it has turned a cuffless ring into a prescribed medical product used across a large clinical network.
Hilo is the only rival close enough to challenge that lead today. It has sold more devices, raised far more capital and built the strongest consumer experience, but its U.S. medical clearance is narrower than its broader wellness pitch.
The most important divide in this market is not ring versus wristband versus patch. It is whether a company has built a regulated care workflow or is still asking customers and investors to believe that one will emerge later.
Sky Labs and Hilo have both reached meaningful scale, but their headline numbers measure different things. Sky Labs reports prescriptions and medical institutions, while Hilo reports devices sold, so neither figure should be treated as a clean market-share comparison.
Biobeat is stronger than its lower visibility suggests. Its FDA-cleared patch has a clear clinical job replacing uncomfortable 24-hour ambulatory cuffs, although public evidence of broad commercial use remains thin.
Calibration is still the category's central compromise. Hilo and Biobeat reduce technical risk by using conventional cuff calibration, while Vital Signals is betting that a calibration-free ring can remove the biggest remaining inconvenience.
Clinical evidence is uneven rather than absent. Hilo has the cleaner published test of stability over time, Sky Labs has the deepest disclosed development dataset, and Vital Signals has a potentially important 451-person study that still needs full publication and independent scrutiny.
Hardware scale and healthcare scale are separate advantages. Hilo has proved it can manufacture and support a six-figure installed base, while Sky Labs has proved it can work through hospitals, prescriptions, reimbursement and pharmaceutical distribution partners.
The strongest moat currently belongs to Sky Labs because its advantage is more than sensor design. A rival would need to recreate physician familiarity, clinical reports, hospital integration, regulatory history and international distribution relationships together.
The ranking could move quickly. Hilo could take the lead with strong U.S. retention, insurer adoption or broader FDA claims, while Vital Signals could jump into the top group if its calibration-free ring ships on time and performs reliably outside controlled studies.
For now, Sky Labs ranks first, Hilo second and Biobeat third. Vital Signals has the highest upside among the earlier challengers, while LiveMetric and Valencell still lack the recent commercial evidence needed to stay close to the leaders.
This market map, featured in our wearable technology market deck, highlights top companies and startups in the wearable technology market
Which wearable blood pressure startups are actually in the race?
The real wearable blood pressure startup race currently has six credible names: Sky Labs, Hilo, Biobeat, LiveMetric, Vital Signals and Valencell.
We define this market narrowly. The device must be worn on the wrist, finger or chest and estimate systolic and diastolic blood pressure without repeatedly inflating a conventional arm cuff. We include products already used by patients, regulated devices entering commercialization and late-stage products close enough to launch that they could change the ranking.
We exclude ordinary wrist cuffs, smartphone-camera apps and university prototypes. We also exclude Samsung, Huawei, Apple, Omron and Whoop because they are established companies rather than startups. Oura remains outside the comparison because it does not currently provide blood pressure readings.
Nanowear is a borderline case. Its SimpleSense platform has explored cuffless blood pressure monitoring, but Nanowear is building a broader clinical monitoring system rather than competing mainly through a blood pressure wearable.
Funding figures require caution. Several companies have mixed equity rounds, grants and strategic investments, while some financing databases disagree. The table therefore uses disclosed totals where possible and rounded estimates elsewhere.
| Startup | What it is building | Approximate funding raised |
|---|---|---|
| Hilo, formerly Aktiia | Optical wristband and calibration cuff for frequent home monitoring | More than $119 million |
| Biobeat | Disposable chest patch for clinical 24-hour blood pressure monitoring | At least $50 million disclosed |
| Sky Labs | Medical and consumer rings for 24-hour blood pressure monitoring | Approximately $40.5 million |
| Valencell | Calibration-free optical blood pressure technology and a fingertip device | Approximately $37.6 million |
| LiveMetric | Watch-like monitor that senses pressure above the radial artery | Approximately $24 million |
| Vital Signals | Calibration-free Signal Ring for everyday blood pressure tracking | More than $15 million |
Is one wearable blood pressure startup clearly ahead today?
Sky Labs is currently ahead overall, with Hilo close behind and Biobeat leading a narrower U.S. clinical niche.
Sky Labs has passed the point where a cuffless blood pressure wearable is merely an interesting device. Its CART BP pro ring has received Korean medical approval, entered an established reimbursement pathway and accumulated more than 250,000 prescriptions across over 1,700 medical institutions. That is the strongest evidence in the market that doctors are repeatedly using the product with real patients.
Hilo has built the largest visible consumer business. The company had sold more than 120,000 devices before beginning its latest U.S. expansion, with approvals or certifications across Europe, Canada, Australia, Saudi Arabia and the United States. Hilo also has far more capital than Sky Labs and a longer history of people wearing its product at home.
The remaining gap is clinical depth. Hilo's current U.S. Hilo Core package is presented as a wellness product, even though the company separately received FDA clearance for its G0 system. Sky Labs has made its regulated medical product central to its commercial model rather than running medical and wellness propositions side by side.
Biobeat belongs in the leading group because its chest patch has multiple FDA clearances and a clear use case in 24-hour ambulatory monitoring. Still, it has not published patient or clinic volumes comparable with the numbers disclosed by Sky Labs and Hilo.
This is a narrow top two, not a runaway winner. Sky Labs leads medical adoption. Hilo leads consumer reach. Biobeat remains a serious specialist challenger.
If you want more recent data on this point, please see our latest wearable technology market report.
As this chart shows, and as featured in our wearable technology market deck, search interest in smart rings has been increasing rapidly
Which wearable blood pressure startup has the strongest commercial traction?
Sky Labs has the strongest real-world commercial traction because its adoption comes through prescriptions and medical institutions rather than preorders, pilots or loosely defined users.
More than 250,000 cumulative prescriptions give Sky Labs a level of proven demand that no other cuffless blood pressure startup has publicly matched. Its presence across over 1,700 medical institutions also shows that adoption is spread across a network rather than concentrated in one research hospital or commercial pilot.
Hilo is the clear number two. Its more than 120,000 device sales represent genuine consumer purchases, and that already separates Hilo from startups that have regulatory clearance but disclose little evidence of recurring demand.
The two numbers cannot be compared perfectly. One Hilo device can stay with a customer for years, while a patient may receive more than one Sky Labs prescription. Even with that limitation, both companies operate at a scale that LiveMetric, Vital Signals, Valencell and Biobeat have yet to demonstrate publicly.
Sky Labs has also reached this point with roughly one-third of Hilo's disclosed funding. Turning prescriptions and device sales into a fake precision ratio would be silly, but the broad conclusion is hard to avoid: Sky Labs has converted its capital into visible clinical activity unusually well.
Biobeat is raising money to expand commercialization. It has a credible product and regulatory base, but widespread U.S. use still needs to be proven. LiveMetric has an older FDA clearance without a visible commercial breakout, while Signal Ring remains at the preorder stage.
Which wearable blood pressure startup is gaining ground fastest now?
Sky Labs is gaining the most meaningful ground right now, while Vital Signals is generating the loudest early buzz.
Sky Labs has recently added several pieces that reinforce the same strategy. CART BP pro received CE-MDR certification, Otsuka Pharmaceutical agreed to handle its planned Japanese hospital rollout, and Sky Labs has started presenting its blood pressure data platform to pharmaceutical companies running clinical trials. The company is widening its business from individual monitoring toward real-world evidence and drug-development data.
Vital Signals has made the fastest entrance. The company raised more than $15 million, opened preorders for a $399 Signal Ring and says initial deliveries will begin later this year. Its pitch is unusually clean: blood pressure from a ring, no calibration cuff and no subscription.
That momentum is still based on promises. Vital Signals must manufacture multiple ring sizes, ship on time, publish full validation evidence and show that calibration-free readings remain stable outside controlled testing. Strong preorder interest would not answer any of those questions.
Hilo is also moving quickly through its U.S. launch. The company now has an active American storefront and is marketing frequent blood pressure tracking through Hilo Core. The catch is that Hilo Core is described as a wellness product, while the separately cleared G0 system comes with a narrower FDA indication.
Biobeat has lately added both money and distribution support. Its $50 million Series B and partnership with Kestra Medical Technologies give it a credible path into U.S. cardiology. We still need patient volumes, clinic counts or completed tests before calling that commercial acceleration.
If you want more recent data on this point, please see our latest wearable technology market report.
This chart, included in our wearable technology market deck, illustrates yearly VC funding for wearable technology startups
Which wearable blood pressure startup has the most mature product?
Sky Labs has the most mature medical product, while Hilo has the most mature everyday consumer experience.
CART BP pro already fits into a real hypertension workflow. A doctor can prescribe the ring, the patient can wear it during normal activities and sleep, and the resulting report can help identify nighttime hypertension, morning surges, masked hypertension or changes after medication.
Hilo has the stronger history of long-term home use. Its European wristband has been sold since 2021 and is designed to collect readings quietly throughout the day and night. Hilo has therefore had several years to improve its app, calibration process, battery management and customer support.
The U.S. product story is more complicated. The FDA-cleared G0 system requires regular cuff calibration and has a defined spot-checking indication. Hilo Core uses the same broader technology family but is currently marketed as a wellness system rather than a medical device. Consumers may not notice that distinction, but doctors and regulators will.
Biobeat is highly mature for one specific job: replacing an uncomfortable inflatable ambulatory cuff during a prescribed 24-hour test. Its disposable chest patch makes less sense as a permanent lifestyle wearable, although permanent wear is unnecessary for the clinical task it targets.
LiveMetric has a cleared device design, but product maturity also requires dependable distribution, support and repeated customer use. Public evidence of those elements has remained limited.
Signal Ring is more advanced than a laboratory prototype because people can now preorder it. Until customers receive the rings and use them for several months, questions around sizing, signal loss, battery life and calibration drift remain unanswered.
Which wearable blood pressure startup has the strongest regulatory position?
Sky Labs has the broadest regulatory position across real clinical use, while Hilo owns the most important U.S. consumer clearance.
Sky Labs has combined Korean medical approval with an established payment pathway and routine use by clinicians. It has since added CE-MDR certification, giving the company a route into European markets once local distribution and reimbursement are in place.
Hilo's FDA clearance was a genuine breakthrough for the category. The FDA's K250415 summary covers the G0 Blood Pressure Monitoring System as an over-the-counter device for adults aged 22 to 59. The cleared use is narrower than the idea of effortless continuous medical monitoring, because the system requires regular calibration with an oscillometric cuff and is indicated for spot checks.
Biobeat has the deepest set of U.S. professional clearances. Its system can be used in hospitals, clinics, long-term-care facilities and homes under professional direction. The patch still depends on cuff calibration, but its intended clinical role is clearer than that of most consumer wearables.
LiveMetric received FDA clearance in 2022 for clinical use in adults. That remains a valuable asset, although the company has not followed it with the geographic expansion or visible adoption achieved by the leaders.
Vital Signals currently sells Signal Ring as a consumer preorder. Valencell has spent years developing calibration-free optical technology, but its proposed fingertip monitor has not reached a verified FDA clearance.
| Startup | Strongest regulatory position | Main limitation |
|---|---|---|
| Sky Labs | Korean medical approval, clinical payment pathway and CE-MDR certification | No disclosed U.S. clearance |
| Hilo | FDA-cleared over-the-counter G0 system and European Class IIa device | U.S. indication requires regular cuff calibration and covers spot checks |
| Biobeat | Multiple FDA clearances for professional patch-based monitoring | Calibration-dependent and aimed mainly at prescribed tests |
| LiveMetric | FDA 510(k) clearance for LiveOne | Narrower clinical use and limited visible expansion |
| Vital Signals | Consumer preorder launch | No medical clearance |
| Valencell | Longstanding optical sensing program | No verified clearance for its own blood pressure product |
This chart, included in our wearable technology market deck, shows why Whoop is leading in wearable technology
Which wearable blood pressure startup has the best clinical evidence?
Hilo has the cleanest published long-term validation, while Sky Labs has the larger development dataset and stronger proof that clinicians will use the technology.
Hilo's most useful published study followed 91 adults for one month under an extended ISO 81060-2 protocol. The wristband stayed within the protocol's accuracy requirements, including among participants with different skin pigmentation and levels of forearm hair. A month is still short, but it addresses calibration stability better than a single laboratory session.
Sky Labs built its algorithm from 320,535 arterial-line blood pressure samples collected from 4,185 people. That is the largest disclosed development dataset among the startups we reviewed. Smaller device studies have also reported mean systolic and diastolic differences within accepted numerical limits.
The studies answer different questions. Hilo provides clearer published evidence that a finished wearable can remain stable after calibration. Sky Labs provides stronger evidence of dataset depth and far more evidence that doctors consider the finished product usable.
LiveMetric published an invasive-reference study involving 34 patients. Its correlations and average errors looked promising, although such a small cohort cannot settle performance across different ages, skin tones, movements and cardiovascular conditions.
Vital Signals says Signal Ring met ISO criteria in a 451-person multicenter study. That could become one of the strongest studies in the category. For now, only the company's summary is available, so we cannot inspect the complete protocol, error distribution or failure rate.
Biobeat has several clinical publications and FDA-reviewed submissions, but its evidence is spread across different cardiovascular measurements and use cases. A direct modern comparison with conventional ambulatory blood pressure monitoring would make its position easier to judge.
Are wearable blood pressure monitors accurate enough for medical decisions?
Wearable blood pressure monitors are useful for tracking patterns today, but they are not ready to replace validated arm cuffs for diagnosis or medication changes across the general population.
Most cuffless wearables estimate pressure from optical pulse signals, waveform shape, pulse timing or pressure sensors. Movement, posture, temperature, vascular stiffness and sensor contact can all change the relationship between the observed signal and the person's actual blood pressure.
Average error figures can also hide uncomfortable details. A device may show almost no average bias because high and low errors cancel each other out. A doctor needs to know how often the device produces a large error for one patient, especially when treatment decisions depend on differences of only a few millimetres of mercury.
The American Heart Association has therefore stopped short of recommending cuffless devices as replacements for validated cuffs in clinical care. Recent FDA guidance follows the same logic. Manufacturers are expected to test initial accuracy, stability over time and the ability to follow genuine blood pressure changes rather than merely reproducing values close to calibration.
Hilo and Biobeat reduce some uncertainty by using cuff calibration, although that weakens the promise of removing cuffs completely. Sky Labs has earned greater clinical trust within its approved use, but broader independent testing would still help. Signal Ring could remove one of the category's biggest inconveniences if its calibration-free design works consistently, yet company claims and shipped performance are two different levels of evidence.
For now, these products make the most sense for observing trends, nighttime patterns and changes between conventional measurements. A validated upper-arm cuff remains the safer reference when a reading could alter treatment.
If you want more recent data on this point, please see our latest wearable technology market report.
This chart, included in our wearable technology market deck, illustrates yearly funding for wearable technology startups
Which wearable blood pressure startup has the easiest product to live with?
Hilo currently offers the easiest proven daily experience, while Signal Ring has the cleaner promise on paper.
Hilo's wristband is small, screenless and designed to work quietly while the user goes through an ordinary day. It can collect around 25 readings over 24 hours, including during sleep, and its battery lasts roughly ten days. A recent independent review found the band comfortable enough for continuous wear and broadly consistent with a conventional home monitor during testing.
The trade-off is calibration. Hilo users still need a companion cuff, and the exact calibration schedule varies between product versions and regulatory markets. The system also requires an active membership in its current commercial packages.
Signal Ring removes almost every visible inconvenience from the pitch. The $399 ring promises background blood pressure tracking, no calibration and no subscription. It is also easier to wear alongside a watch than another wristband would be.
None of that has been tested by a large customer base yet. A ring can perform badly when the size is slightly wrong, and fingers experience temperature and blood-flow changes that can affect optical measurements. Vital Signals will have to prove that its smooth purchase proposition survives daily use.
Sky Labs offers a strong clinical form factor. Its ring can run for up to roughly 72 hours, enough for a prescribed monitoring period without an inflatable cuff interrupting sleep. Biobeat may be even easier during a single 24-hour test, although wearing an adhesive chest patch every day would appeal to fewer consumers.
Which wearable blood pressure startup can deliver at scale?
Hilo has the strongest proof of hardware manufacturing, while Sky Labs has built the better healthcare delivery system.
Hilo had already shipped more than 120,000 devices before its latest expansion. Producing that many wristbands, cuffs and accessories requires reliable suppliers, quality control, fulfilment and customer support. It also exposes product weaknesses that rarely appear in a clinical study involving fewer than 100 people.
Sky Labs has placed its system across more than 1,700 medical institutions. That demands a different kind of scale: hospital procurement, clinician training, regulated reporting, technical support and coordination with distributors. Those capabilities are harder to see than a factory line, but they often decide whether a medical device spreads.
Sky Labs has deliberately used established healthcare companies rather than building every national sales force itself. That approach helped it expand in Korea and gives it a realistic route into Japan.
Biobeat's patch creates both an opportunity and a burden. Disposable sensors can generate repeat revenue whenever a new test is ordered, but the company must continuously manufacture and distribute consumables at predictable quality. Its latest financing gives it the resources to try, though the output figures remain private.
Vital Signals faces the clearest manufacturing test. It must produce a medical-style sensor in multiple ring sizes, ship sizing kits, manage exchanges and maintain consistent optical contact across thousands of fingers. The company has not completed that test yet.
This chart, included in our wearable technology market deck, compares the main business model options for wearable technology brands
Which wearable blood pressure startup has won the strongest partners?
Sky Labs has won the strongest strategic partners because its agreements directly support prescriptions, hospital sales and entry into new countries.
Otsuka Pharmaceutical's planned Japanese commercialization of CART BP pro is the clearest example. Otsuka already works with doctors treating cardiovascular disease and can place the ring inside an existing medical sales channel. That relationship is far more useful than a general partnership announcement with no defined buyer or distribution role.
Sky Labs previously worked with Daewoong Pharmaceutical in Korea and Omron Healthcare on Japanese consumer distribution. The repeated pattern is easy to see: Sky Labs develops the sensing and data platform, while established healthcare companies provide local access.
Biobeat's Kestra Medical Technologies partnership is also strategically useful. Kestra sells wearable cardiac technology and works with high-risk cardiovascular patients, giving Biobeat a natural group of clinicians and patients to target. The partnership includes investment, licensing and product-development elements rather than a vague commitment to explore opportunities.
Hilo's biggest customer asset is its direct consumer base. What remains less visible is a deep enterprise contract with a major insurer, health system or employer that pays for large-scale ongoing use.
LiveMetric once described health systems, insurers and self-insured employers as its target customers. Public evidence that those targets became large recurring contracts has remained scarce. Vital Signals and Valencell have not yet disclosed major buyers for their own finished blood pressure products.
Which wearable blood pressure startup has the hardest lead to copy?
Sky Labs currently has the hardest lead to copy because rivals would need to reproduce its clinical workflow, physician familiarity, regulatory history and international distribution relationships together.
A competitor can build another optical ring. Recreating years of prescription data, hospital integration and doctor trust takes much longer. Sky Labs is also expanding the same dataset into pharmaceutical research and real-world evidence, which could give its platform value beyond the sale of each ring.
Hilo's advantage comes from years of consumer use. Its installed base has produced information about calibration, signal rejection, adherence, nighttime wear and user behaviour. A new wristband could imitate Hilo's hardware quickly, but it would begin without that operating history.
Biobeat has built broader cardiovascular capabilities around its patch, including measurements such as cardiac output and stroke volume in certain approved configurations. That makes the technology more useful in clinical monitoring than a device focused only on systolic and diastolic pressure.
Signal Ring is trying to build the boldest technical advantage. Reliable calibration-free readings would remove the largest remaining hassle in cuffless blood pressure monitoring. Until independent researchers and real customers confirm the results, that advantage remains possible rather than proven.
Large wearable companies remain the main threat to every startup. Apple, Samsung, Huawei and Omron already possess manufacturing scale, established apps and massive distribution. The startups will stay defensible only if their clinical evidence, data or medical workflows remain difficult for those companies to reproduce.
If you want more recent data on this point, please see our latest wearable technology market report.
This chart, featured in our wearable technology market deck, illustrates how revenue is divided among customer segments in the wearable technology market
Is the best-funded wearable blood pressure startup also the leader?
Hilo has the deepest pockets, but Sky Labs has used its capital more efficiently so far.
Hilo has raised more than $119 million, almost three times the amount reported by Sky Labs. That funding has produced a polished consumer system, international approvals, six-figure device sales, a direct brand and entry into the United States. The money has clearly created something substantial.
Sky Labs has reached deeper clinical adoption with around $40.5 million in disclosed funding. We cannot compare every dollar cleanly because the two companies have different products, markets and distribution models. Even so, Sky Labs has achieved more visible medical use with far less capital.
Hilo's higher spending partly reflects its direct-to-consumer strategy. Advertising, fulfilment, support and international subscriptions require more capital than selling through pharmaceutical partners in one home market. Hilo may ultimately be building a larger consumer platform, but that outcome is still ahead of it.
Biobeat's $50 million Series B gives it enough capital to mount a serious U.S. commercialization effort. What we cannot yet see is how efficiently that money turns into completed tests, repeat orders and paying clinics.
Vital Signals is attempting a hardware launch with a comparatively lean funding base. Successful delivery would make the company look capital-efficient. Delays, returns or an expensive regulatory process could change that quickly.
Funding strengthens Hilo's challenge without settling the ranking. Sky Labs has produced the better result per dollar disclosed.
Does one startup lead every part of wearable blood pressure monitoring?
No single startup leads every wearable blood pressure segment because the market currently splits into several distinct jobs.
Sky Labs leads ring-based clinical ambulatory monitoring. Its product is built for doctors who need to understand a patient's daytime and nighttime blood pressure, identify hidden hypertension and review treatment response.
Hilo leads frequent consumer wrist monitoring. It is the strongest choice for people who want to observe their blood pressure patterns over weeks or months without repeatedly stopping to use an arm cuff.
Biobeat leads the patch-based clinical segment in the United States. Its main competitor is the traditional 24-hour ambulatory cuff rather than a smart ring or lifestyle wearable.
Vital Signals is trying to open a new segment around calibration-free consumer rings. Signal Ring could become the category leader quickly because no rival has yet established a large commercial base there.
LiveMetric owns a distinctive radial-artery approach and an FDA clearance, but the company has shown little recent evidence of scaling. Valencell remains technically interesting, especially as a potential sensor supplier, although its own fingertip monitor has not reached a verified regulatory or commercial breakthrough.
The overall ranking depends on which outcome receives the most weight. Hilo wins consumer reach, Biobeat is strong in U.S. clinical patches, and Vital Signals has the most ambitious new product. Sky Labs covers the most valuable combination of medical credibility and actual adoption.
This chart, included in our wearable technology market deck, shows how health monitoring wearable technology has evolved over time
What could change the wearable blood pressure startup ranking?
Hilo is the only current rival that could overtake Sky Labs quickly, although Signal Ring has the largest upside if its calibration-free claims survive real use.
Hilo's next decisive numbers will be active U.S. customers, renewal rates and accepted readings per user. Large consumer sales would become far more valuable if people continue paying and wearing the band after the first year. Broader FDA claims or major insurer adoption would strengthen Hilo even more.
Sky Labs faces a different test. Most of its disclosed use still comes from South Korea. The company must show that its clinical model can travel to Europe and Japan, where approval alone will not guarantee reimbursement or doctor adoption.
Biobeat could move into the top two by disclosing strong U.S. utilization. Thousands of completed tests, large cardiology networks or regular patch reorders would carry more weight than another financing or partnership announcement.
Vital Signals must ship Signal Ring, publish its complete validation results and show that readings remain dependable across movement, temperature changes, skin tones and cardiovascular conditions. Success on those points would put pressure on both Hilo and Sky Labs.
An incumbent could also reorder the field. A major wearable company offering validated systolic and diastolic readings to millions of existing users would instantly dominate distribution. The startups would then have to defend themselves through medical approvals, specialist data and closer integration with care.
Which wearable blood pressure startups are actually ahead?
Sky Labs is the wearable blood pressure startup ahead overall today.
Sky Labs leads on the evidence that carries the most weight in a regulated health category: medical adoption, clinical integration, product maturity and a credible route into additional countries. Its more than 250,000 reported prescriptions across over 1,700 medical institutions put it ahead of a market where several competitors still discuss launches, partnerships or future commercialization.
Hilo ranks a close second. It has the largest proven consumer business, the strongest funding position and the clearest chance of overtaking Sky Labs. Its current weakness is the gap between its broad wellness proposition and the narrower conditions attached to its U.S. medical clearance.
Biobeat ranks third because its FDA-cleared patch solves a real clinical problem and now has serious financial backing. The missing piece is visible adoption.
Vital Signals takes fourth place despite being much earlier. Its calibration-free ring could change the category, but a preorder and a company-reported study cannot yet outweigh shipped products and medical use.
LiveMetric remains ahead of Valencell because it possesses an FDA-cleared finished device. Its limited recent momentum keeps it well behind the top four. Valencell has valuable sensing expertise, but its own blood pressure product has yet to emerge as a verified commercial contender.
| Rank | Startup | Why it holds this position |
|---|---|---|
| 1 | Sky Labs | The strongest combination of prescribed use, hospital adoption, medical maturity and international expansion |
| 2 | Hilo | The clear consumer leader, with large device sales, deep funding and U.S. potential, but a less convincing clinical position |
| 3 | Biobeat | A credible FDA-cleared clinical patch with strong new financing, although commercial scale remains unclear |
| 4 | Vital Signals | The most interesting new challenger, with a calibration-free ring that still needs delivery and independent proof |
| 5 | LiveMetric | An FDA-cleared technology that has not shown enough recent commercial progress |
| 6 | Valencell | A technically experienced company without a verified regulatory or commercial breakthrough for its own monitor |
If you want more recent data on this point, please see our latest wearable technology market report.
In our wearable technology market deck, we identify pain points entrepreneurs should prioritize
OUR METHODOLOGY
This analysis compares the wearable blood pressure startups with the strongest combination of working hardware, clinical evidence, regulatory progress and visible commercialization. We define the category narrowly around devices worn on the wrist, finger or chest that estimate systolic and diastolic blood pressure without repeatedly inflating a conventional arm cuff.
We assessed the companies across commercial traction, medical adoption, product maturity, regulatory position, clinical evidence, recent momentum, scalability, strategic distribution and the durability of each company's advantage. Shipped products, prescriptions, institutional use, regulatory decisions, published studies and defined distribution agreements carried more weight than preorders, planned launches or broad partnership announcements.
We did not combine unlike evidence into a mechanical score. A prescription, a device sale, an FDA clearance and a clinical study demonstrate different forms of progress, so each was interpreted within the product's intended use. The final ranking reflects the pattern across the full body of evidence rather than one headline number.
Funding totals are approximate because company disclosures and financing databases do not always separate equity, grants, debt and strategic investment in the same way. We used disclosed totals where possible and rounded estimates where the available records differed.
Regulatory status was checked against official FDA records and company disclosures for Korean approval, European certification and other market authorizations. We also distinguished clearly between regulated medical products and wellness products, especially where the same company sells related systems under different claims.
Clinical evidence was judged by the reference method, participant count, study duration, publication quality and whether the study tested stability over time rather than accuracy during a single controlled session. We also considered real-world medical use because a technically acceptable device can still fail if clinicians cannot integrate it into routine care.
Key sources included Sky Labs' CART BP pro product and workflow materials, Sky Labs' company history and Korean reimbursement information, Sky Labs' certification, adoption and partnership updates, Hilo's financing, device-sales and international approval disclosure, Hilo's explanation of the distinction between Hilo Core and the FDA-cleared G0 system, and Hilo's current U.S. product information.
We also used the FDA record for Hilo's G0 system, Biobeat's 24-hour blood pressure patch materials, the FDA records for Biobeat BB-613-BPM and Biobeat Platform-2 and BB-613WP Patch, Biobeat's $50 million Series B announcement, and Kestra Medical Technologies' collaboration disclosure.
Additional sources included the FDA clearance record for LiveMetric LiveOne, Valencell's calibration-free fingertip program, the American Heart Association's assessment of cuffless blood pressure devices, the American Heart Association's 2025 high blood pressure guideline summary, the FDA's draft guidance on cuffless device testing, the FDA safety communication on unauthorized blood pressure devices, and the FDA classification and standards page for non-invasive blood pressure systems.
This chart, included in our wearable technology market deck, illustrates how market revenue is distributed across Europe, Asia, North America, Africa, and South America in the wearable technology market
Related blog posts
- Non-invasive glucose monitoring: which startup is ahead?
- Smart rings: which startup is ahead?
